Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




May
27
Today In Oncology
Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States
Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status
FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer
Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma
AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo